Enzychem Lifesciences and Cadila Healthcare, a Zydus Group unit, have signed an agreement to manufacture the first-ever Covid-19 plasmid deoxyribonucleic acid (DNA) vaccine, ZyCoV-D.
The US Food and Drug Administration (FDA) has accepted Enzychem Lifescience’s investigational new drug application (IND) to assess its EC-18 therapeutic candidate for the prevention of acute respiratory disease syndrome (ARDS) due to Covid-19 pneumonia.
Enzychem Lifesciences announced the Ministry of Food and Drug Safety (MFDS, formerly the Korea Food and Drug Administration), has accepted its Investigational New Drug (IND) application to initiate a Phase 2 study for its lead therapeutic candidate.